Overview and Scope
Ovarian cancer diagnostics refers to the methods and procedures used to detect and diagnose ovarian cancer, including assessing symptoms, conducting physical examinations, and performing various diagnostic tests. Ovarian cancer is a malignant tumor that develops in the ovaries, which are part of the female reproductive system.
Sizing and Forecast
The ovarian cancer diagnostics market size has grown strongly in recent years. It will grow from $2.62 billion in 2023 to $2.82 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to growth in biomarker discovery and validation, transvaginal ultrasound adoption, brca gene mutations awareness, research on tumor markers, screening programs and guidelines.
The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.65 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to early detection initiatives, increasing incidence of ovarian cancer, integration of artificial intelligence (ai), personalized medicine approaches, emergence of novel biomarkers, genomic and proteomic profiling. Major trends in the forecast period include biosensor technologies for early detection, digital pathology integration, innovations in imaging modalities, improved imaging technologies, advancements in pathology techniques.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-diagnostics-global-market-report
Segmentation & Regional Insights
The ovarian cancer diagnostics market covered in this report is segmented –
1) By Product Type: Instruments, Kits, Reagents
2) By Diagnosis Type: Biopsy, Blood Test, Imaging, Other Diagnosis Types
3) By Cancer Type: Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Other Cancer Types
4) By End User: Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes
North America was the largest region in the ovarian cancer diagnostic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12022&type=smp
Major Driver Impacting Market Growth
The rise in the prevalence of ovarian cancer is expected to propel the growth of the ovarian cancer diagnostics market going forward. Ovarian cancer is a malignant tumor that develops in the ovaries, the female reproductive organs responsible for producing eggs and hormones. This shift has resulted from increased longevity, delayed childbearing, and lifestyle changes. Ovarian cancer diagnostics can help reduce the prevalence of ovarian cancer by enabling early detection and intervention, leading to timely treatment and improved outcomes. For instance, in February 2022, according to the World Ovarian Cancer Coalition, a Canada-based not-for-profit organization, ovarian cancer affected 313,959 women worldwide in 2020. This will have increased by 42% by 2040 to 445,721; between 2020 and 2040, there will be a 51% increase in the number of women dying from ovarian cancer, from 207,252 to 313,617. Therefore, the rising prevalence of ovarian cancer is driving the growth of the ovarian cancer diagnosis market.
Key Industry Players
Major companies operating in the ovarian cancer diagnostics market report are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., The American Cancer Society, Myriad Genetics Inc., ArcherDX Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc
The ovarian cancer diagnostics market report table of contents includes:
1. Executive Summary
- Ovarian Cancer Diagnostics Market Characteristics
- Ovarian Cancer Diagnostics Market Trends And Strategies
- Ovarian Cancer Diagnostics Market – Macro Economic Scenario
- Global Ovarian Cancer Diagnostics Market Size and Growth
.
- Global Ovarian Cancer Diagnostics Market Competitive Benchmarking
- Global Ovarian Cancer Diagnostics Market Competitive Dashboard
- Key Mergers And Acquisitions In The Ovarian Cancer Diagnostics Market
- Ovarian Cancer Diagnostics Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
